Evidence map›Paper›PMID 36005645›Full record

ArticleMetabolites2022

Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes.

Samantha V Crosby, Izzeldin Y Ahmed, Laura R Osborn, Zeyuan Wang, Mary A Schleiff, William E Fantegrossi, Swati Nagar, Paul L Prather, Gunnar Boysen, Grover P Miller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Samantha V CrosbyDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Izzeldin Y AhmedDepartment of Chemistry and Physics, Department of Biological Sciences, Arkansas State University, Jonesboro, AR 72401, USA.
Laura R OsbornDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Zeyuan WangDepartment of Pharmaceutical Sciences, Temple University, Philadelphia, PA 19122, USA.ORCID 0000-0003-4526-829X
Mary A SchleiffDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0003-3594-6835
William E FantegrossiDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Swati NagarDepartment of Pharmaceutical Sciences, Temple University, Philadelphia, PA 19122, USA.ORCID 0000-0003-2667-7063
Paul L PratherDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-3927-301X
Gunnar BoysenDepartment of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-8364-9881
Grover P MillerDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-4743-8187
University of Arkansas for Medical Sciences · USTemple University · USArkansas State University · US

Funding

Predicting Intracellular Drug Concentrations In The Presence Of TransportersR01GM104178 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI Kenneth Ray Korzekwa, Swati Nagar · 2013 to 2026
$4.0M
Improving prediction of drug interactions mediated by time-dependent inhibitorsR01GM114369 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI KORZEKWA, KENNETH RAY, NAGAR, SWATI · 2016 to 2023
$3.2M
Synthetic Cannabinoid Toxicity: Role of BiotransformationR01DA039143 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2016 to 2020
$2.9M
Drug Enforcement Administration HHSF223201610079CNIDA NIH HHS R01 DA039143NIDA NIH HHS R01DA039143NIGMS NIH HHS R01 GM104178NIGMS NIH HHS R01GM104178NIGMS NIH HHS R01 GM114369NIGMS NIH HHS R01GM114369
6 · The paper itself

Abstract

In 2019, synthetic cannabinoids accounted for more than one-third of new drugs of abuse worldwide; however, assessment of associated health risks is not ethical for controlled and often illegal substances, making CD-1 mouse exposure studies the gold standard. Interpretation of those findings then depends on the similarity of mouse and human metabolic pathways. Herein, we report the first comparative analysis of steady-state metabolism of

Indexed as

5F-AKB485F-APINACACB1 receptordrug abuseenzyme kineticshumanmetabolismmouseP450synthetic cannabinoid

Identifiers

PMID36005645
PMCPMC9413144
OpenAlexW4292686355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.